(NASDAQ: VTVT) Vtv Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.8%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.78%.
Vtv Therapeutics's earnings in 2026 is -$4,756,000.On average, 8 Wall Street analysts forecast VTVT's earnings for 2026 to be -$5,538,791, with the lowest VTVT earnings forecast at -$6,974,891, and the highest VTVT earnings forecast at -$4,193,238. On average, 8 Wall Street analysts forecast VTVT's earnings for 2027 to be -$18,383,030, with the lowest VTVT earnings forecast at -$24,722,115, and the highest VTVT earnings forecast at -$10,835,992.
In 2028, VTVT is forecast to generate -$19,439,544 in earnings, with the lowest earnings forecast at -$26,737,083 and the highest earnings forecast at -$16,108,677.